Safety and efficacy of fidaxomicin and vancomycin in children and adolescents with Clostridioides (Clostridium) difficile infection: a phase 3, multicenter, randomized, single-blind clinical trial (SUNSHINE).
Fidaxomicin, a narrow-spectrum antibiotic approved for Clostridioides (Clostridium) difficile infection (CDI) in adults, is associated with lower rates of recurrence than vancomycin; however, pediatric data are limited. This multicenter, investigator-blind, phase 3, parallel-group trial assessed safety and efficacy of fidaxomicin in children. Patients aged <18 years with confirmed CDI were randomized 2:1 to ten days of treatment with fidaxomicin (suspension or tablets, twice daily) or vancomycin (suspension or tablets, four times daily). Safety assessments included treatment-emergent adverse events (TEAEs). The primary efficacy endpoint was confirmed clinical response (CCR), 2 days after end of treatment (EOT). Secondary endpoints included global cure (GC; CCR without CDI recurrence) 30 days after EOT (end of study; EOS). Plasma and stool concentrations of fidaxomicin and its active metabolite OP-1118 were measured. Of 148 patients randomized, 142 were treated (30 <2 years old). The proportion of participants with TEAEs was similar with fidaxomicin (73.5%) and vancomycin (75.0%). Of three deaths in the fidaxomicin arm during the study, none were CDI or treatment related. The rate of CCR at 2 days after EOT was 77.6% (76/98) with fidaxomicin and 70.5% (31/44) with vancomycin, while the rate of GC at EOS was significantly higher in participants receiving fidaxomicin (68.4% versus 50.0%; adjusted treatment difference 18.8%; 95% CI 1.5%, 35.3%). Systemic absorption of fidaxomicin and OP-1118 was minimal and stool concentrations were high. Fidaxomicin was well tolerated and demonstrated significantly higher rates of GC, compared with vancomycin, in children and adolescents with CDI.